Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma

American Journal of Respiratory Cell and Molecular Biology

Volumn 19, Issue 2, 1998, Pages 333-337

  Schwarzenberger, Paul ^b   Lei, Dinghua ^b   Freeman, Scott M ^b   Ye, Peng ^b   Weinacker, Ann ^b   Theodossiou, Chris ^b   Summer, Warren ^b   Kolls, Jay K ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ANIMAL; ARTICLE; CBA MOUSE; CELL CULTURE; ENZYMOLOGY; GENE THERAPY; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; MALE; MESOTHELIOMA; MOUSE; PATHOLOGY;

ANIMALS; GANCICLOVIR; GENE THERAPY; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, INBRED CBA; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0032133392     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.19.2.3123     Document Type: Article

References (25)

1. Price, B. 1997. Analysis of current trends in United States mesothelioma incidence. Am. J. Epidemiol. 145:211-218.
2. de Klerk, N. H., and B. K. Armstrong. 1992. The epidemiology of asbestos and mesothelioma. In Malignant Mesothelioma. D. W. Henderson, editor. Hemisphere, New York, 223-250.
3. Upham, J. W., M. J. Garlepp, A. W. Musk, and B. W. S. Robinson. 1995. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 50:887-893.
4. Moolten, F. L. 1986. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46:5276-5281.
5. Freeman, S. M., C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, F. L. Moolten, and G. N. Abraham. 1993. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:5274-5283.
6. Elshami, A. A., J. C. Kucharczuk, H. B. Zhang, W. R. Smythe, H. C. Hwang, I., A. Litzky, I., R. Kaiser, and S. M. Albelda. 1996. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Ther. 7:141-148.
7. Smythe, W. R., L. R. Kaiser, H. C. Hwang, K. M. Amin, J. M. Pilewski, S. J. Eck, J. M. Wilson, and S. M. Albelda. 1994. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann. Thorac. Surg. 57:1395-1401.
8. Smythe, W. R., H. C. Hwang, A. A. Elshami, K. M. Amin, S. L. Eck, B. L. Davidson, J. M. Wilson, L. R. Kaiser, and S. M. Albelda. 1995. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222:78-86.
9. Hwang, H. C., W. R. Smythe, A. A. Elshami, J. C. Kucharczuk, K. M. Amin. J. P. Williams, L. A. Litzky, L. R. Kaiser, and S. M. Albelda. 1995. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol. 13:7-16.
10. Elshami, A. A., J. C. Kucharczuk, D. H. Sterman, W. R. Smythe, H. C. Hwang, K. M. Amin, L. A. Litzky, S. M. Albelda, and L. R. Kaiser. 1995. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222:298-310.
11. Kolls, J. K., K. Allen, D. Lei, A. Weinacker, S. Freeman, and W. R. Summer. 1996. Comaprative efficacy of killing a mesothelioma cell line by delivery of the HSVtk gene with a permanently transduced cell line versus an adenoviral vector. J. Invest. Med. 44:62A. (Abstr.)
12. Freeman, S. M., C. McCune, W. Robinson, C. N. Abboud, G. N. Abraham, C. Angel, and A. Marrogi. 1995. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum. Gene Ther. 6:927-939.
13. Fick, J., F. G. Barker, P. Dazin, E. M. Westphale, E. C. Beyer, and M. A. Israel. 1995. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92:11071-11075.
14. Elshami, A. A., A. Saavedra, H. Zhang, J. C. Kucharczuk, D. C. Spray, G. I. A. K. Fishman, L. R. Kaiser, and S. M. Albelda. 1996. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3:85-92.
15. Freeman, S. M., R. Ramesh, M. Shastri, A. Munshi, A. K. Jensen, and A. J. Marrogi. 1995. The role of cytokines in mediasting the bystander effect using HSV-TK xenogenic cells. Cancer Lett. 92:167-174.
16. Freeman, S. M., R. Ramesh, and A. J. Marrogi. 1997. Immune system in suicide-gene therapy. Lancet 349:2-3.
17. Ramesh, R., A. J. Marrogi, A. Munshi, C. N. Abboud, and S. M. Freeman. 1996. In vivo analysis of the 'bystander effect:' a cytokine cascade. Exp. Hematol. 24:829-838.
18. Ramesh, R., A. Munshi, C. N. Abboud, A. J. Marrogi, and S. M. Freeman. 1996. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther. 3:373-384.
19. Davis, M. R., L. S. Manning, D. Whitaker, M. J. Garlepp, and B. W. S. Robinson. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52:881-886.
20. Rosenfeld, M. E., M. Wang, G. P. Siegal, R. D. Alvarez, G. Mikheeva, V. Krasnykh, and D. T. Curiel. 1996. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med. 74:455-462.
21. Kolls, J., K. Peppel, M. Silva, and B. Beutler. 1994. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 91:215-219.
22. Kucharczuk, J. C., A. A. Elshami, H. B. Zhang, W. R. Smythe, H. C. Hwang, J. S. Tomlinson, K. M. Amin, L. A. Litzky, S. M. Albelda, and L. R. Kaiser. 1995. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann. Thorac. Surg. 60:593-598.
23. Treat, J., and S. Albelda. 1996. Phase I trial of AdRSVtk virus with ganciclovir in patients with unresectable malignant mesothelioma. Hum. Gene Ther. 7:2053-2057.
24. Whartenby, K. A., C. N. Abboud, A. J. Marrogi, R. Ramesh, and S. M. Freeman. 1995. Biology of disease: the biology of cancer gene therapy. Lab. Invest. 72:131-145.
25. Mesnil, M., C. Piccoli, G. Tiraby, K. Willecke, and H. Yamasaki. 1996. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA 93:1831-1835.